Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1350 of 1475 entries
View as:

Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)

Phase: N/A Priority: Normal
NCT ID: NCT02368522 Org: User:
Start: 12/31/14 End: 02/28/17 Due: 02/28/18

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03956680 Org: User:
Start: 03/26/19 End: 04/24/24 Due: 04/24/25

Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea

Phase: N/A Priority: Normal
NCT ID: NCT02727933 Org: User:
Start: 11/03/15 End: 07/05/20 Due: 07/05/21

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT04493541 Org: User:
Start: 08/26/20 End: 04/21/23 Due: 04/21/24

Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00529763 Org: User:
Start: 11/17/07 End: 04/20/22 Due: 04/20/23

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01466374 Org: User:
Start: 12/31/11 End: 12/31/14 Due: 12/31/15

Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates

Phase: N/A Priority: Normal
NCT ID: NCT02845089 Org: User:
Start: 02/29/16 End: 08/15/17 Due: 08/15/18

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Phase: N/A Priority: Normal
NCT ID: NCT01741545 Org: User:
Start: 03/31/13 End: 01/31/15 Due: 01/31/16

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Phase: N/A Priority: Normal
NCT ID: NCT03044873 Org: User:
Start: 02/02/17 End: 03/27/17 Due: 03/27/18

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01068704 Org: User:
Start: 06/30/10 End: 12/31/10 Due: 12/31/11

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03994601 Org: User:
Start: 09/06/19 End: 08/31/24 Due: 08/31/25

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01762462 Org: User:
Start: 12/31/12 End: 03/31/13 Due: 03/31/14

A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)

Phase: N/A Priority: Normal
NCT ID: NCT05335031 Org: User:
Start: 03/03/21 End: 11/30/29 Due: 11/30/30

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02790125 Org: User:
Start: 07/28/16 End: 11/07/17 Due: 11/07/18

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03035734 Org: User:
Start: 01/25/17 End: 02/07/17 Due: 02/07/18

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03873402 Org: User:
Start: 06/21/19 End: 08/29/25 Due: 08/29/26

An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism

Phase: N/A Priority: Normal
NCT ID: NCT00847782 Org: User:
Start: 03/31/09 End: 09/30/09 Due: 09/30/10

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00886782 Org: User:
Start: 05/31/09 End: 08/04/10 Due: 08/04/11

Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT02856451 Org: User:
Start: 12/09/15 End: 12/31/20 Due: 12/31/21

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00743938 Org: User:
Start: 03/31/09 End: 06/30/12 Due: 06/30/13

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04470778 Org: User:
Start: 07/20/20 End: 03/28/21 Due: 03/28/22

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01928394 Org: User:
Start: 10/24/13 End: 11/18/24 Due: 11/18/25

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02714218 Org: User:
Start: 04/04/16 End: 05/28/21 Due: 05/28/22

A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

Phase: N/A Priority: Normal
NCT ID: NCT06851065 Org: User:
Start: 08/22/24 End: 06/30/25 Due: 06/30/26

Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden

Phase: N/A Priority: Normal
NCT ID: NCT02492828 Org: User:
Start: 06/30/14 End: 01/31/16 Due: 01/31/17